$22.38
2.75% today
Nasdaq, Feb 28, 04:47 pm CET
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Rigel Pharmaceuticals, Inc. Stock price

$21.78
+0.06 0.28% 1M
+8.57 64.88% 6M
+4.96 29.49% YTD
+6.78 45.20% 1Y
-3.32 13.23% 3Y
+1.38 6.76% 5Y
-8.12 27.16% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.55 2.46%
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Key metrics

Market capitalization $383.65m
Enterprise Value $382.77m
P/E (TTM) P/E ratio 100.55
EV/FCF (TTM) EV/FCF 35.71
EV/Sales (TTM) EV/Sales 2.43
P/S ratio (TTM) P/S ratio 2.44
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 18.97%
Revenue (TTM) Revenue $157.47m
EBIT (operating result TTM) EBIT $9.50m
Free Cash Flow (TTM) Free Cash Flow $10.72m
Cash position $61.11m
EPS (TTM) EPS $0.22
P/E forward 55.98
P/S forward 2.23
EV/Sales forward 2.23
Short interest 3.25%
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
157 157
19% 19%
100%
- Direct Costs 17 17
355% 355%
11%
141 141
9% 9%
89%
- Selling and Administrative Expenses 108 108
1% 1%
69%
- Research and Development Expense 21 21
43% 43%
13%
11 11
164% 164%
7%
- Depreciation and Amortization 1.92 1.92
55% 55%
1%
EBIT (Operating Income) EBIT 9.50 9.50
150% 150%
6%
Net Profit 3.88 3.88
116% 116%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
3 days ago
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025.
Neutral
PRNewsWire
about one month ago
First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase (...
Neutral
PRNewsWire
about 2 months ago
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDS Rigel anticipates 2025 total revenue of approximately $200 to $210 million SOUTH SAN FRANCISC...
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 147
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today